Full-Time

Accounting Manager

Posted on 8/29/2024

Metagenomi

Metagenomi

201-500 employees

Develops genome editing tools for therapeutics

Compensation Overview

$135k - $170k/yr

+ Equity + Bonuses + Comprehensive Benefits

Senior

Oakland, CA, USA

The role is based in Emeryville, California, and has the potential to be hybrid.

Category
Financial Accounting
Financial Controller
Management Accounting
Accounting
Required Skills
NetSuite
Coupa
Requirements
  • CPA or finance/accounting degree and at least five years of relevant accounting experience.
  • Public accounting experience and biotech industry experience, preferred.
  • Advanced proficiency or evidence of ability to gain advanced proficiency in NetSuite, Coupa, and FloQast.
  • Strong working knowledge of Excel and Word
  • Strong critical thinking and problem-solving skills
  • Ability to quickly translate guidance into action and to demonstrate an ability to produce high-quality work with strong attention to detail independently
  • Highly collaborative, solutions-oriented approach
  • Effective oral and written communication skills, specifically when collaborating with other departments with limited knowledge of accounting
  • Ability to work in a fast-paced and dynamic environment
Responsibilities
  • Assist in the design and execution of month-end, quarter-end, and year-end close activities, including preparing critical journal entries and performing key account reconciliations; focus areas are likely to include accounting for fixed assets, accruals, and revenue.
  • Take an active role in special projects focused on improving the quality and efficiency of accounting processes and help to streamline and shorten the close process; the role may include fully implementing the NetSuite fixed asset module and leading annual internal fixed asset audits to ensure appropriate tracking and tagging.
  • Partner with leaders in the Research and Development teams to develop and maintain robust accrued CMO and CRO expense models, especially for quarter-end accruals.
  • Manage the AP Team, which currently consists of two AP Accountants.
  • Support the procure-to-pay process, including approval of requisitions and invoices
  • Play a leadership role in developing SOX documentation across all areas of responsibility and participate in walkthroughs with the auditors for relevant cycles
  • Contribute to preparing PBCs for quarterly reviews and year-end audits and responding to auditor questions promptly.

Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to discover and collect genetic material, which is then sequenced and engineered into potential therapies. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly analyze billions of proteins to identify effective genome editing tools. This approach sets them apart from competitors who may not leverage such advanced technologies. The goal of Metagenomi is to create curative treatments for diseases through gene editing, aiming to significantly impact the healthcare market.

Company Size

201-500

Company Stage

IPO

Headquarters

Emeryville, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Metagenomi's platform can address a full spectrum of genetic diseases.
  • The company is well-capitalized with $248.3 million to support operations into 2027.
  • Bayer's $275 million investment indicates strong industry support for Metagenomi.

What critics are saying

  • The termination of the $3 billion Moderna partnership impacts financial projections.
  • Class action lawsuits could lead to financial liabilities and damage reputation.
  • Metagenomi's lack of clinical-stage candidates may affect near-term revenue generation.

What makes Metagenomi unique

  • Metagenomi uses metagenomics to discover novel genome editing systems for therapeutics.
  • The company leverages AI and high-throughput screening for rapid discovery of novel proteins.
  • Metagenomi's gene editing systems are ultra-small, efficient, and have decreased immune response risk.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

18%
BioSpace
Mar 18th, 2025
Metagenomi Reports Business Updates And Full Year 2024 Financial Results

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025 Well capitalized with $248.3 million in cash, cash equivalents and available-for-sale marketable securities at the end of Q4 2024; Cash runway anticipated to support operating plans into 2027 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the full year ended December 31, 2024, and provided business updates. “Our diverse and modular AI-driven metagenomics platform is designed to precisely target any site in the human genome, yielding the potential to address the full spectrum of genetic diseases,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “In 2024, we made significant progress toward our goal of developing curative genetic medicines for patients. We progressed MGX-001, our potentially transformative treatment for hemophilia A, and leveraged the MGX-001 platform to advance an additional wholly-owned program for an undisclosed secreted protein deficiency disorder

Stock Titan
Jan 8th, 2025
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

GlobeNewswire
Nov 6th, 2024
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds investors that a class action lawsuit has been filed against Metagenomi, Inc. and encourages investors to contact the firm.

Accesswire
Nov 5th, 2024
MGX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

MGX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC announces that Metagenomi, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit!

Business Wire
Oct 2nd, 2024
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX)

Glancy Prongay & Murray LLP reminds investors of looming deadline in the Class action lawsuit against Metagenomi, Inc. (MGX).

INACTIVE